WallStreetZenWallStreetZen

NASDAQ: ATHE
Alterity Therapeutics Revenue

OverviewForecastEarningsRevenue
DividendOwnership
Alterity Therapeutics revenue was $2.34M for the trailing 12 months ending Dec 31, 2024, with N/A growth year over year. Quarterly revenue for the quarter (Q4 2024) ending on Dec 31, 2024 was N/A, down N/A from last quarter. For the last reported fiscal year 2024 ending Jun 30, 2024, ATHE annual revenue was $2.7M, with -0.8% growth year-over-year.

ATHE past revenue growth

How has ATHE's revenue growth performed historically?

Company
-0.89%
Industry
497.69%
Market
20.68%
ATHE's revenue has grown slower... subscribe to Premium to read more.
Revenue Growth vs Industry Performance
ATHE's revenue has grown slower... subscribe to Premium to read more.
Revenue Growth vs Market Performance
ATHE's revenue growth is accelerating... subscribe to Premium to read more.
Accelerating Revenue Growth Performance

ATHE revenue history

Current Revenue
$2.3M
Current Earnings
-$12.3M
Current Profit Margin
-531.3%

Be the first to know when ATHE announces revenue.

ATHE Revenue History By Year

ATHE Yearly RevenueATHE RevenueATHE ChangeATHE Revenue Growth
2024-06-30$2.68M-$21.40k-0.79%
2023-06-30$2.70M-$857.08k-24.09%
2022-06-30$3.56M$185.65k+5.51%
2021-06-30$3.37M$3.29M+3,884.34%
2020-06-30$84.64k-$3.40M-97.57%
2019-06-30$3.49M$1.17M+50.59%
2018-06-30$2.32M-$9.75k-0.42%
2017-06-30$2.33M-$1.32M-36.22%
2016-06-30$3.65M-$1.36M-27.13%
2015-06-30$5.00M-$2.73M-35.27%
2014-06-30$7.73M$3.49M+82.28%
2013-06-30$4.24M$1.66M+64.09%
2012-06-30$2.58M$2.41M+1,380.01%
2011-06-30$174.62k-$7.44k-4.08%
2010-06-30$182.06k-$164.38k-47.45%
2009-06-30$346.43k-$124.88k-26.50%
2008-06-30$471.32k$40.56k+9.41%
2007-06-30$430.76k-$348.96k-44.75%
2006-06-30$779.72k-$1.24M-61.38%
2005-06-30$2.02M$407.15k+25.26%
2004-06-30$1.61M$393.67k+32.31%
2003-06-30$1.22M$770.99k+172.36%
2002-06-30$447.31k$184.89k+70.45%
2001-06-30$262.42k$215.26k+456.45%
2000-06-30$47.16kN/AN/A

1 of 2

Alterity Therapeutics Revenue FAQ

What was ATHE's revenue last quarter?

Alterity Therapeutics (NASDAQ: ATHE) reported Q4 2024 revenue of N/A up N/A year over year. In the same quarter last year, Alterity Therapeutics's revenue was N/A.

What was Alterity Therapeutics's revenue in 2024?

Alterity Therapeutics's annual revenue for the twelve months ending Jun 30, 2024 was $2.68 million, a 0.79% decrease year over year.

How much does Alterity Therapeutics make in a day?

Based on Alterity Therapeutics annual revenue for the past five years, ATHE makes an average of $6,792.02 per day.

What was Alterity Therapeutics's annual revenue growth in the past year?

As of Q2 2025, Alterity Therapeutics's revenue has grown -0.89% year over year. This is 498.59 percentage points lower than the US Biotechnology industry revenue growth rate of 497.69%. Alterity Therapeutics's revenue in the past year totaled $2.34 million.

How much does Alterity Therapeutics make in a year?

Alterity Therapeutics's revenue by year for the past five years is:
  • Alterity Therapeutics's revenue for the twelve months ending Jun 30, 2024 was $2.68 million, a 0.79% decrease year over year.
  • Alterity Therapeutics's annual revenue for Jun 30, 2023 was $2.70 million, a 24.09% decrease from 2022.
  • Alterity Therapeutics's annual revenue for 2022 was $3.56 million, a 5.51% increase from 2021.
  • Alterity Therapeutics's annual revenue for 2021 was $3.37 million, a 3,884.34% increase from 2020.
  • Alterity Therapeutics's annual revenue for 2020 was $84.64 thousand, a 97.57% decrease from 2019.
©2025 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.